U10 DA013714/DA/NIDA NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2006	2
2007	6
2008	4
2009	8
2010	13
2011	18
2012	12
2013	23
2014	23
2015	16
2016	10
2017	12
2018	9
2019	8
2020	6
2021	9
2022	4
2023	3
2024	0

1

Supporting Practice Facilitators in a Learning Health Care System.

Parchman M, Ike B, Osterhage K, Johnson A, Baldwin LM. Parchman M, et al. Perm J. 2023 Sep 15;27(3):3-6. doi: 10.7812/TPP/23.035. Epub 2023 Aug 4. Perm J. 2023. PMID: 37537988 Free PMC article. No abstract available.

2

Exploring the mediating role of baseline urinalysis results on demographic characteristics and stimulant use disorder treatment outcomes.

Smith CL, Miguel AQ, Keever A, Bowden T, Burduli E, Roll J, McPherson SM. Smith CL, et al. J Subst Use Addict Treat. 2023 Aug;151:208962. doi: 10.1016/j.josat.2023.208962. Epub 2023 Jan 26. J Subst Use Addict Treat. 2023. PMID: 36801204 Clinical Trial.

3

Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: Impact of drug type and participant characteristics.

Ruglass LM, Shevorykin A, Zhao Y, Killeen TK, Bauer AG, Morgan-López AA, Back SE, Fitzpatrick S, López-Castro T, Norman SB, Saavedra LM, Hien DA. Ruglass LM, et al. Drug Alcohol Depend. 2023 Mar 1;244:109769. doi: 10.1016/j.drugalcdep.2023.109769. Epub 2023 Jan 14. Drug Alcohol Depend. 2023. PMID: 36696843 Free PMC article. Clinical Trial.

4

Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes.

Bunting AM, Krawczyk N, Choo TH, Pavlicova M, McNeely J, Tofighi B, Rotrosen J, Nunes E, Lee JD. Bunting AM, et al. J Subst Abuse Treat. 2022 Dec;143:108830. doi: 10.1016/j.jsat.2022.108830. Epub 2022 Jun 22. J Subst Abuse Treat. 2022. PMID: 35773113 Free PMC article. Clinical Trial.

5

Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone.

Na PJ, Scodes J, Fishman M, Rotrosen J, Nunes EV. Na PJ, et al. J Clin Psychiatry. 2022 Apr 18;83(3):21m14140. doi: 10.4088/JCP.21m14140. J Clin Psychiatry. 2022. PMID: 35452194 Clinical Trial.

6

Predictors of therapeutic alliance, treatment feedback, and clinical outcomes among African American women in treatment for co-occurring PTSD and SUD.

Bauer AG, Ruglass LM, Shevorykin A, Saraiya TC, Robinson G, Cadet K, Julien L, Chao T, Hien D. Bauer AG, et al. J Subst Abuse Treat. 2022 Aug;139:108766. doi: 10.1016/j.jsat.2022.108766. Epub 2022 Mar 22. J Subst Abuse Treat. 2022. PMID: 35346534 Free PMC article. Clinical Trial.

7

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Roache JD, Pavlicova M, Campbell A, Choo TH, Peavy M, Kermack AS, Nunes EV Jr, Rotrosen J. Roache JD, et al. Alcohol Clin Exp Res. 2021 Dec;45(12):2569-2578. doi: 10.1111/acer.14729. Epub 2021 Nov 23. Alcohol Clin Exp Res. 2021. PMID: 34698397 Free PMC article.

8

Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.

Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. Zhu Y, et al. Drug Alcohol Depend. 2021 Nov 1;228:108996. doi: 10.1016/j.drugalcdep.2021.108996. Epub 2021 Aug 28. Drug Alcohol Depend. 2021. PMID: 34555691 Free PMC article. Clinical Trial.

9

Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.

Bagley SM, Chavez L, Braciszewski JM, Akolsile M, Boudreau DM, Lapham G, Campbell CI, Bart G, Yarborough BJH, Samet JH, Saxon AJ, Rossom RC, Binswanger IA, Murphy MT, Glass JE, Bradley KA; PROUD Collaborative. Bagley SM, et al. Addict Sci Clin Pract. 2021 Jul 7;16(1):46. doi: 10.1186/s13722-021-00249-3. Addict Sci Clin Pract. 2021. PMID: 34233750 Free PMC article.

10

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.

Nunes EV Jr, Scodes JM, Pavlicova M, Lee JD, Novo P, Campbell ANC, Rotrosen J. Nunes EV Jr, et al. Am J Psychiatry. 2021 Jul;178(7):660-671. doi: 10.1176/appi.ajp.2020.20060816. Epub 2021 Jun 25. Am J Psychiatry. 2021. PMID: 34170188 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

150 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year